The developme nt of parotid gland lymphoepithelia l cysts in the early stages of human immun odeficiency virus (HIV) infection is considered a precursor to acquired immunodeficiency syndrome (AIDS).l It is usually associated with lymphadenopath y, fatigue, night sweats, diarrhea, and weight loss. Associated opportunis-tic infections or malignant neoplasms might not be present in this early stage."
In the case illustrated here, an 18-year-old man was evaluated for bilateral painless parotid gland swelling of 1 month ' s duration. He had been previously diagnosed with HIV infection, and his CD4 count was 202 cells/ul. Get patients pain-free almost afull day sooner. 1 @ CIPRO®HC Otic ends ear pain 19,2hours faster than afluoroquinolone with no steroid @ The only steroid/fluoroquinolone combination for otitis externa @ Convenient 3-2-7 dosing (3 drops, 2times/day for 7 days)
IMAGING CLINIC
He was otherwise asymptomatic. Computed tomography (CT) detected bilateral parotid cysts and bilateral lymphadenopathy in the posterior cervical spaces (figure) . The differential diagnosis of parotid gland enlargement in an HIV-positive patient includes reactive lymphadenopathy (follicul ar hyperplasia), parotid cyst formation, and diffu se infiltration ofthe gland by lymphoid elements accompanied by cystic dilation of the salivary ducts (diffuse infiltrative lymphocytosis syndromej .P Sjogren 's syndrome is also a consideration when there is enlargement of the parotid glands, with or without HIV infection. The histolog ic distinction between AIDS-related parotid lymphoepithelial cysts and the cystic benign lymphoepithelial lesions of Sjogren's syndrome is that in AIDS , the cysts occur in the parotid lymph nodes, whereas in Sjogren 's syndrome, they occur in the parotid parenchyma . ' The lymph nodes in the parotid glands are known to contain salivary gland acini and ducts. Since lymphoid tissue is vulnerable to HIV infection, intranodal epithelial proliferation can occur, causing cyst formation. Submandibular gland cysts have also been observed in HIVpositive patient s, but this appears to be uncommon."
Parotid gland lymphoepithelial cysts are painless and slow-growing. They can suggest the presence of HIV infection in a patient with cervical lymphadenopathy. These cysts usually involve the superficial parotid lobe bilaterally. Multiple cysts are more common than single cysts. Their size varies from 0.5 to 5 ern in diameter.' Clinical symptom s of HIV infection can involve virtually any body system, including the salivary glands.' CT, ultrasound, and magnetic resonance imaging are effective in detecting parotid gland cysts and cervicallymphadenopathy . . Fertility studies perf ormed in rats at oral doses of cipronoxacn up to 100 mglkglday reveai ed no evidence of impairment. This wouid be over 1000 times the maximum recommended Clinical doseof ototopical ciprofloxacin based uponbody surface area, assumingtotalabsorptionof ciprofloxacinfromthe ear ofapatient treat ed wi th CIPRO"HC OTIC twice perday. Long term st udies have not been performed to evaluate the carcinogenic potential or the effect on fertil ityoftopical hydrocorti sone. Mutagenici tystudies with hydrocort isonewere negati ve. Pregnancy: Teratogenic Effects. Pregnancy Category C: Reproduction studies have been perf ormed in rats and mice usi ngoral doses of up to 100mglkg and IV doses upto 30 mglkg and have reveal ednoevcence of harm to thefetusasa resultof cipronoxacin. In rabbits,ciprofloxacln(30and 100mlJlkg ora lly)producedgastrointestina l disturbances resulting inma ternalweight lossand an increased lncidenceof abortion,butno ter atogeni city was observedatei ther dose. Afterintravenousadministration ofdoses upto 20mglkg, no mat ernaltoxicitywas produced intherabbit, andnoembryotoxlCltyor teratogenicitywas observed. Cort icoster oids are generally teratogenic in laboratory animals when administered systemically at relati vel y low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermalapplicationinlaborat oryani mals. Animal reproduction studies have not been conducted wi th CIPRO' HC OTiC. No adequate and well controlled studies have been perf ormed in pregnant women. Caution should be exercised when CIPRO' HCOTIC is used by a pregnantwoman. Nursing Mothers: Ciprofloxacin is excreted in humanmi lk with systemic use. It is not known whether ciprofloxacinis excreted in human mil k foll owing topical oticadministration. Becauseof the potentiaifor serious adverse reactions innursing infants, adeci sionshould be madewhether todi scontinuenursing or . todiscont inuethe drug,taking Into account theImportance ofthedrugtothemother. Pediatric use: The safety and efficacy of CIPRO' HC OTIC have been established in pediatric patients 2 years and older (131 pati ents) in adequate and well-controlled clinical trial s. Alt hough no data are availabie on pat rents less than age 2 years, there are no known safety concernsor differencesin the diseaseprocess inthispopulationwhichwould precludeuseof this productin patientsone year and older. See DOSAGE AND ADMINISTRATION. AOVERSE REACTIONS InPhase 3 cli nical trials, a total of 564 patients were treat ed wi th CIPRO' HCOTIC. Adverse eventswith at least remoterel ationship to treatment included headache (1.2%) and pruritus (0.4%). 
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